Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: J Surg Res. 2021 Feb 22;263:44ā€“52. doi: 10.1016/j.jss.2021.01.010

Figure 3. Increased presence of CD8+ and CD8+ central memory circulating lymphocytes in tumor bearing animals in the presence or absence of LIGHT and/or IL-2.

Figure 3

An increased percentage of CD8+ peripheral blood mononuclear cells was observed in soluble and liposomal IL-2 treated mice with LT expressing tumors. Soluble IL-2 treated mice bearing WT-tumor did not experience an increase in circulating CD8+ cells (upper left). The percent of CD4+ (upper middle) and CD8+ (upper right) T-cells expressing CD44+CD62L+ (central memory T-cells) increased with soluble and liposomal IL-2 treatment. These differences were not observed in WT-tumor bearing mice. The percent of circulating CD8+ T-cells expressing CD44+CD62Lāˆ’ (effector memory T-cells) significantly decreased in soluble and IL-2 treated mice with LIGHT expressing tumors (lower left). The percent of circulating CD4+ T-cells expressing CD44+CD62Lāˆ’ decreased in liposomal IL-2 treated mice with LIGHT expressing tumors (lower middle). Differences in circulating CD4+CD44+CD62Lāˆ’ cells were not observed in WT-tumor bearing mice. *p<0.05, **p<0.01, ***p<0.001. Oncolipin= liposomal IL-2. Wild-type (WT) tumor bearing animal data are labeled, and on the left in each panel to the LIGHT (LT) expressing tumor bearing animal data.